Novartis, Ionis' experimental heart drug misses key goal in closely watched trial ↧ ↧ Novartis, Ionis' experimental heart drug misses key goal in closely... Novartis said on Friday its experimental drug pelacarsen did not cut the risk of major heart attacks and strokes in patients with a genetic risk factor in a late-stage trial, marking a setback to the Swiss drugmaker's efforts to revive its drug pipeline.
published
Novartis, Ionis' experimental heart drug misses key goal in closely watched trial ↧
Open the original public source →
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.